Bone

BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds

Retrieved on: 
Monday, October 30, 2023
FDM, Medical device regulation, Medtech, MDR, Bone, Injury, CT, Workflow, Orthopedic surgery, ISO, Sterilization, 3D printing, Medical device, Traumatology

The presentation titled "Semi-automated workflow for the design and fabrication of 3D-printed patient-specific resorbable scaffolds for the treatment of large segmental bone defects while complying with MDR regulations" outlined the potential of BellaSeno´s novel resorbable scaffolds for curing large segmental bone defects (> 5cm size).

Key Points: 
  • The presentation titled "Semi-automated workflow for the design and fabrication of 3D-printed patient-specific resorbable scaffolds for the treatment of large segmental bone defects while complying with MDR regulations" outlined the potential of BellaSeno´s novel resorbable scaffolds for curing large segmental bone defects (> 5cm size).
  • The scaffold is needed to hold the autologous bone graft in position for optimal vascularization and bone healing.
  • Scaffolds made by additive manufacturing from bioresorbable polymers represents a highly attractive opportunity to produce such patient-specific open-pore scaffolds.
  • This results in a new generation of high-performance bone scaffolds which are well suited for the biological reconstruction of large bone defects."

Defeat Duchenne Canada and Parent Project Muscular Dystrophy Award $300,000 (USD) Clinical Fellowship in Duchenne Endocrinology and Bone Fragility

Retrieved on: 
Friday, November 3, 2023
Fertility, Steroid, Children's Hospital of Eastern Ontario, CHEO, Research, APRN, Louisiana Family Forum, Canada Research Chair, Bone, Endocrinology, Organization, Chronic kidney disease-mineral and bone disorder, University of Ottawa Heart Institute, Adrenal insufficiency, Vamorolone, Prednisone, PPMD, Male, Growth, Gender identity, Muscle weakness, University of Ottawa, Risk, Consortium, Duchenne muscular dystrophy, Partnership, DRS, University, Osteoporosis, Weakness, USD, Puberty, Education, DMD, Fracture, Muscular dystrophy, Hospital, Calvarial doughnut lesions-bone fragility syndrome, Human, Nursing, Dietary supplement, Medical device, Pediatrics, Duchenne

WASHINGTON and OTTAWA, ON, Nov. 3, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Defeat Duchenne Canada, Canada's leading charity fighting to defeat Duchenne, today announced a collaborative research award of $300,000 (USD) in support of two Clinical Fellowships in Duchenne Endocrinology and Bone Fragility. The three-year award will sponsor the extended fellowship of Dr. Kim Phung, as well as new fellow Dr. Rana Halloun, under the guidance of Dr. Leanne Ward, Professor of Pediatrics and Research Chair in Pediatric Bone Disorders at the University of Ottawa.

Key Points: 
  • Duchenne is the most common muscular dystrophy in children, affecting approximately one in 5,000 live male births.
  • Duchenne is caused by a change in the dystrophin gene that leads to progressive muscle weakness.
  • In 2021, Dr. Phung was awarded a two-year fellowship in pediatric endocrine and bone diseases at the University of Ottawa, with specific focus on endocrine and bone complications of Duchenne.
  • Ward and Phung will delve into the latest developments and crucial topics related to bone health, growth, puberty, and adrenal insufficiency for Duchenne muscular dystrophy.

Spinal Cord Injury Market Likely to Exhibit Substantial Growth by 2032, Assesses DelveInsight | Companies to Watch Out - NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, AbbVie

Retrieved on: 
Wednesday, November 1, 2023
LAS, United Kingdom, Triage, MRI, X-ray, Spine, Bone, Literature, SCI, Unaware, Rehabilitation, Intubation, QOL, Disease, Neurogenic shock, Development, Quality of life, Growth, Transport, Phenylephrine, Norepinephrine, Tetraplegia, CT, Spinal cord, Accident, Thrombus, AbbVie, Regenerative medicine, Trauma, Patient, Diagnosis, Bradycardia, VA, Pharmaceutical industry, Medical device, Trapping, Medical imaging, Research

LAS VEGAS, Nov. 1, 2023 /PRNewswire/ -- DelveInsight's Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.
  • Spinal cord injury represents a significant medical condition that results in a wide range of functional, psychological, and socioeconomic challenges.
  • The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries.
  • To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs
    Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
    MT-3921: Mitsubishi Tanabe Pharma America Inc.

Spinal Cord Injury Market Likely to Exhibit Substantial Growth by 2032, Assesses DelveInsight | Companies to Watch Out - NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, AbbVie

Retrieved on: 
Wednesday, November 1, 2023
LAS, United Kingdom, Triage, MRI, X-ray, Spine, Bone, Literature, SCI, Unaware, Rehabilitation, Intubation, QOL, Disease, Neurogenic shock, Development, Quality of life, Growth, Transport, Phenylephrine, Norepinephrine, Tetraplegia, CT, Spinal cord, Accident, Thrombus, AbbVie, Regenerative medicine, Trauma, Patient, Diagnosis, Bradycardia, VA, Pharmaceutical industry, Medical device, Trapping, Medical imaging, Research

LAS VEGAS, Nov. 1, 2023 /PRNewswire/ -- DelveInsight's Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.
  • Spinal cord injury represents a significant medical condition that results in a wide range of functional, psychological, and socioeconomic challenges.
  • The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries.
  • To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs
    Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
    MT-3921: Mitsubishi Tanabe Pharma America Inc.

Frazier Life Sciences Announces Addition of Veteran Drug Developer and Entrepreneur to Team

Retrieved on: 
Tuesday, October 31, 2023
Alzheimer's disease, Dyslipidemia, FDA, Stroke, Obesity, International development, Heart, Fracture, Migraine, Oligonucleotide, Drug development, A-DNA, FLS, Amgen, Science, Osteoporosis, Anemia, Woman, Pain, Patient, Heart failure, Bone, Metabolism, Pharmaceutical industry, Latigo, Neuroscience

MENLO PARK, Calif., Oct. 31, 2023 /PRNewswire/ -- Frazier Life Sciences (FLS) is excited to introduce Scott Wasserman, M.D.

Key Points: 
  • MENLO PARK, Calif., Oct. 31, 2023 /PRNewswire/ -- Frazier Life Sciences (FLS) is excited to introduce Scott Wasserman, M.D.
  • as the latest member of its venture partners team, bringing more than two decades of expertise in drug development across diverse therapeutic areas.
  • "Scott's proficiency and unwavering commitment to scientific rigor in drug development perfectly complements Frazier Life Sciences' data-driven methodology, underscoring our aligned missions."
  • "I'm delighted to join Frazier Life Sciences and contribute to the company's proven approach to venture creation," remarks Scott Wasserman, M.D., venture partner at FLS.

Titanium Emerges as the Dominant Material in Trauma Fixation Devices, Backed by Biocompatibility and Strength-to-Weight Ratio - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 19, 2023
Medical Devices, Health, WHO, DSM-IV codes, Dislocation, Injury, Fixation (psychology), Ageing, Fatality, Bone, United Nations, Human musculoskeletal system, Prevalence, External fixation, Rheumatoid arthritis, Osteoporosis, Trauma, Ambulatory Surgery Center Association, Traffic, Tissue, United, World Health Organization, Risk, Internal, Osteoarthritis, USD, Disability, Accident, Stainless steel, Woman, Tendon, Internal fixation, Elective surgery, Fracture, Specialization, Dentistry, Dietary supplement, Nursing, Growth, Hospital, Titanium

Trauma fixation devices, a crucial component of trauma care, play a vital role in the treatment of bone fractures and tissue degeneration.

Key Points: 
  • Trauma fixation devices, a crucial component of trauma care, play a vital role in the treatment of bone fractures and tissue degeneration.
  • These incidents often result in bone fractures and dislocations, necessitating the use of trauma fixation devices for the repair of bone-related deformities.
  • Internal fixators, which play a crucial role in orthopedic and trauma surgeries for stabilizing bones and tissues, dominate the trauma fixation devices market.
  • In terms of material, the Trauma Fixation Devices Market is divided into Stainless Steel, Titanium, and Others.

Bioretec Ltd's Board of Directors has decided on a new option program 2023-1

Retrieved on: 
Friday, October 20, 2023
Black, Health care, Person, Annual general meeting, Trauma, EUR, Consultant, USD, Black–Scholes model, Patient, Bone, Health insurance, Security (finance), Music, Life insurance

A maximum total of 1,000,000 option rights will be issued, and they will entitle their owners to subscribe for a maximum total of 1,000,000 new shares in the company.

Key Points: 
  • A maximum total of 1,000,000 option rights will be issued, and they will entitle their owners to subscribe for a maximum total of 1,000,000 new shares in the company.
  • The option rights will be issued free of charge.
  • The theoretical market value of one option right is approximately EUR 1.283 and the theoretical market value of all option rights combined is approximately EUR 1,283,357.
  • Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants.

Bioretec Ltd's Board of Directors has decided on a new option program 2023-1

Retrieved on: 
Friday, October 20, 2023
Black, Health care, Person, Annual general meeting, Trauma, EUR, Consultant, USD, Black–Scholes model, Patient, Bone, Health insurance, Security (finance), Music, Life insurance

A maximum total of 1,000,000 option rights will be issued, and they will entitle their owners to subscribe for a maximum total of 1,000,000 new shares in the company.

Key Points: 
  • A maximum total of 1,000,000 option rights will be issued, and they will entitle their owners to subscribe for a maximum total of 1,000,000 new shares in the company.
  • The option rights will be issued free of charge.
  • The theoretical market value of one option right is approximately EUR 1.283 and the theoretical market value of all option rights combined is approximately EUR 1,283,357.
  • Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants.

Play Yellow Celebrates its 5th Anniversary with a Commitment to Children's Hospitals

Retrieved on: 
Thursday, October 19, 2023
Golf, Geisinger, Bone, Human, Children's Miracle Network Hospitals, Health, PGA, Jack Nicklaus, SALT, Children's Hospital, Liver cancer, Hospital, Love, Patient, Ewing sarcoma, Fireworks, Health insurance, Toy, Nursing

SALT LAKE CITY, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Jack and Barbara Nicklaus, together with the PGA TOUR and Children's Miracle Network Hospitals, are proud to celebrate the 5th anniversary of Play Yellow, a program dedicated to supporting pediatric patients treated at member hospitals.

Key Points: 
  • "Play Yellow was born out of our love for children and our passion for making a difference," said Jack and Barbara Nicklaus.
  • The 5th-anniversary celebration of Play Yellow took place earlier this week at the annual Play Yellow Invitational in West Palm Beach, FL, from October 15 to 17, 2023.
  • His annual Play Yellow golf tournament, the NEPA Invitational, supports the Geisinger Janet Weis Children's Hospital, a member hospital of Children's Miracle Network Hospitals.
  • Play Yellow allows the golf community to give back to the areas in which they play and support.

Legal-Bay Lawsuit Funding Spearheads New Department to Focus on Construction Accidents and Lawsuits Involving New York Labor Law and Texas Gulf of Mexico Jones Act

Retrieved on: 
Wednesday, October 18, 2023
Falls, NP-hardness, Element, Slip, Burns, Explosion, Chronic pain, Personal injury, Bone, Construction, Workplace, Head injury, Lawsuit, Crush injury, Injury, Rachel Flowers, Accident, Electrocution, Fire, Health insurance, Insurance

HOUSTON, Oct. 18, 2023 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Pre-Settlement Funding Company, announced today that they are spearheading a new, specialized department to tackle the majority of lawsuit funding requests they've recently received for hard workers injured in construction site accidents, manual labor accidents, personal injury incidents involving heavy duty equipment, Jones Act worker's comp. and Fela cases, some of which fall under N.Y. labor law personal injury. These work-related cases include various injuries and elements such as collisions, demolition injury, crush injury, equipment malfunction, electrocution, slip and fall, gas leak, trench collapse, ground collapse, explosions, crane incidents, burns, falls, tree falls, shoulder injuries, back injuries, slipped discs, bone fractures, broken bones, fires, head injury, and traumatic brain injury. Also, damages can be rewarded due to the simple fact that you can no longer work and have lost wages or loss of wage claims.

Key Points: 
  • Lawsuit Cash Advance Firm shifts gears in market and branches out to niche cases involving workplace accidents and labor law violations nationally.
  • and Fela cases, some of which fall under N.Y. labor law personal injury.
  • Legal-Bay—a leader in lawsuit funding services and legal funding and a champion for plaintiffs—funds all types of workplace accident cases.
  • According to labor laws in place in most states, workers are entitled to safe working conditions on their job site.